First Turn Management LLC Trims Stock Position in Oric Pharmaceuticals, Inc. $ORIC

First Turn Management LLC lessened its position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,010,307 shares of the company’s stock after selling 149,167 shares during the quarter. Oric Pharmaceuticals comprises approximately 1.9% of First Turn Management LLC’s portfolio, making the stock its 25th largest position. First Turn Management LLC owned about 2.06% of Oric Pharmaceuticals worth $16,444,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Oric Pharmaceuticals by 48.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after buying an additional 1,525,445 shares during the period. State Street Corp raised its position in shares of Oric Pharmaceuticals by 77.1% during the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after buying an additional 1,854,458 shares during the period. Orbimed Advisors LLC raised its position in shares of Oric Pharmaceuticals by 305.0% during the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after buying an additional 2,742,475 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Oric Pharmaceuticals by 114.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,939,285 shares of the company’s stock valued at $15,863,000 after buying an additional 1,034,473 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Oric Pharmaceuticals by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 1,750,694 shares of the company’s stock valued at $14,323,000 after buying an additional 119,950 shares during the period. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Stock Up 5.8%

Shares of NASDAQ ORIC opened at $8.27 on Friday. The firm has a market cap of $856.11 million, a price-to-earnings ratio of -5.74 and a beta of 1.04. Oric Pharmaceuticals, Inc. has a 52-week low of $7.23 and a 52-week high of $14.93. The business’s 50 day moving average is $9.03 and its two-hundred day moving average is $10.17.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). Analysts anticipate that Oric Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on ORIC shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Wall Street Zen lowered Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Stifel Nicolaus began coverage on Oric Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $14.00 target price on the stock. Citigroup cut their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Finally, Benchmark reissued a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.92.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.